Shandong Sinobioway Biomedicine Co Ltd Asset Resilience Ratio
Shandong Sinobioway Biomedicine Co Ltd asset resilience ratio. Shandong Sinobioway Biomedicine Co Ltd (002581) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002581 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shandong Sinobioway Biomedicine Co Ltd (2018–2025)
Asset resilience ratio of Shandong Sinobioway Biomedicine Co Ltd from 2018 to 2025. This chart shows how Shandong Sinobioway Biomedicine Co Ltd's Asset Resilience Ratio has changed over time. Read Shandong Sinobioway Biomedicine Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shandong Sinobioway Biomedicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shandong Sinobioway Biomedicine Co Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥20.10K | 0.0% |
| Total Liquid Assets | CN¥20.10K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Shandong Sinobioway Biomedicine Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shandong Sinobioway Biomedicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shandong Sinobioway Biomedicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Shandong Sinobioway Biomedicine Co Ltd Asset Resilience Ratio by Year (2018–2025)
Shandong Sinobioway Biomedicine Co Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Shandong Sinobioway Biomedicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | CN¥20.10K ≈ $2.94K |
CN¥2.17 Billion ≈ $317.30 Million |
-3.03pp |
| 2018-12-31 | 3.03% | CN¥130.00 Million ≈ $19.02 Million |
CN¥4.29 Billion ≈ $628.26 Million |
-- |
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. It offers injectable mouse nerve growth factor, human interferon, vaccines, traditional Chinese medicine decoction pieces, and pharmaceutical distribution. The company was founded in 1998 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Y… Read more